文献速递胸部肿瘤

仑伐替尼联合帕博利珠单抗、培美曲塞和铂类作为转移性非鳞状非小细胞肺癌一线治疗:3期LEAP-006研究

Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study.
PubMed 文献 · J Thorac Oncol · 2025-05-24

LEAP-006研究纳入748例无靶向基因改变的IV期非鳞状非小细胞肺癌患者,随机接受仑伐替尼或安慰剂联合帕博利珠单抗+培美曲塞+铂类。最终分析时中位随访36.8个月,两组中位无进展生存期12.1 vs 9.5个月(HR 0.88,95%CI 0.74-1.05,单侧p=0.07976),中位总生存期21.8 vs 22.1个月(HR 1.05,95%CI 0.88-1.26,单侧p=0.70818),差异均未达统计学显著。结论为加用仑伐替尼未改善疗效,帕博利珠单抗联合化疗仍是标准治疗。

要点

  • 仑伐替尼组与安慰剂组的中位无进展生存期分别为12.1个月和9.5个月,未达统计学显著(HR 0.88,95%CI 0.74-1.05,单侧p=0.07976)。
  • 两组中位总生存期分别为21.8个月和22.1个月,未达统计学显著(HR 1.05,95%CI 0.88-1.26,单侧p=0.70818)。
  • 仑伐替尼组与安慰剂组≥3级治疗相关不良事件发生率分别为69.7%和55.6%,5级分别为5.6%和2.7%。

核心结论

  • 在无靶向基因改变的IV期非鳞状非小细胞肺癌中,仑伐替尼联合帕博利珠单抗+化疗对比帕博利珠单抗+化疗未改善疗效,无新安全性信号,帕博利珠单抗联合化疗仍是该人群的标准治疗。

研究设计与样本

  • LEAP-006(NCT03829319)为3期研究,第1部分为仑伐替尼+帕博利珠单抗+化疗的开放标签安全性导入,第2部分为随机双盲研究。
  • 研究纳入既往未经治疗、无靶向基因改变的IV期非鳞状非小细胞肺癌成人患者748例,按1:1随机分配至仑伐替尼组(n=375)或安慰剂组(n=373)。
  • 给药方案为仑伐替尼8 mg每日一次或安慰剂每日一次,联合帕博利珠单抗200 mg每3周一次及培美曲塞+卡铂或顺铂4个周期,后续帕博利珠单抗(总计≤35个周期)和培美曲塞直至疾病进展或不可耐受毒性。
  • 主要终点为无进展生存期和总生存期。

主要发现

  • 最终分析(2023年8月11日)时总生存期中位随访36.8个月。
  • 仑伐替尼组与安慰剂组的中位无进展生存期分别为12.1个月(95%CI 10.4-14.1)和9.5个月(95%CI 8.3-10.7),HR 0.88(95%CI 0.74-1.05),单侧p=0.07976。
  • 仑伐替尼组与安慰剂组的中位总生存期分别为21.8个月(95%CI 18.6-24.0)和22.1个月(95%CI 19.7-24.2),HR 1.05(95%CI 0.88-1.26),单侧p=0.70818。
  • 仑伐替尼组与安慰剂组的≥3级治疗相关不良事件发生率分别为69.7%和55.6%,5级分别为5.6%和2.7%。

关键数值与推荐

  • 仑伐替尼组中位无进展生存期12.1个月(95%CI 10.4-14.1)vs 安慰剂组9.5个月(95%CI 8.3-10.7),HR 0.88(95%CI 0.74-1.05),单侧p=0.07976。
  • 仑伐替尼组中位总生存期21.8个月(95%CI 18.6-24.0)vs 安慰剂组22.1个月(95%CI 19.7-24.2),HR 1.05(95%CI 0.88-1.26),单侧p=0.70818。
  • 仑伐替尼组≥3级治疗相关不良事件发生率69.7% vs 安慰剂组55.6%,5级分别为5.6% vs 2.7%。

临床怎么用

  • 帕博利珠单抗联合化疗仍是该人群(无靶向基因改变的IV期非鳞状非小细胞肺癌)的标准治疗。
  • 在帕博利珠单抗联合化疗基础上加用仑伐替尼未改善疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We present the LEAP-006 (NCT03829319) phase 3 study evaluating the addition of lenvatinib to first-line pembrolizumab plus chemotherapy in metastatic nonsquamous NSCLC. METHODS: Adults with previously untreated stage IV nonsquamous NSCLC without targetable genetic alterations were randomized 1:1 to lenvatinib 8 mg/d or placebo once daily plus pembrolizumab 200 mg every 3 weeks with pemetrexed and carboplatin or cisplatin for 4 cycles, followed by pembrolizumab (≤35 total cycles) and pemetrexed until disease progression or intolerable toxicity. Primary end points were progression-free survival and overall survival (OS). Part 1 was an open-label safety run-in of lenvatinib plus pembrolizumab and chemotherapy; part 2 was the randomized, double-blind study. RESULTS: Participants (n = 748) were randomized to the lenvatinib (n = 375) or placebo (n = 373) arms. Median follow-up at final analysis (August 11, 2023) for OS was 36.8 months. Median (95% confidence interval [CI]) progression-free survival was 12.1 (10.4-14.1) versus 9.5 (8.3-10.7) months in the lenvatinib and placebo arms, respectively (hazard ratio, 0.88 [95% CI, 0.74-1.05]; 1-sided p = 0.07976). Median (95% CI) OS was 21.8 (18.6-24.0) versus 22.1 (19.7-24.2) months (hazard ratio, 1.05 [95% CI, 0.88-1.26]; 1-sided p = 0.70818). Grade 3 or higher treatment-related adverse events occurred in 69.7% and 55.6% of participants, respectively (grade 5, 5.6% versus 2.7%). CONCLUSIONS: Adding lenvatinib to first-line pembrolizumab plus chemotherapy did not improve efficacy versus pembrolizumab plus chemotherapy in stage IV nonsquamous NSCLC without targetable genetic alterations. There were no new safety signals. Pembrolizumab plus chemotherapy remains a standard of care for this population. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov/), NCT03829319.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Herbst RS, Cho BC, Zhou C, et al. Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study. J Thorac Oncol. 2025. PMID: 40419140. doi:10.1016/j.jtho.2025.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。